Chelsea: Trading Strategies For The Pending FDA Decision
moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click here to view […]
CHTP
Chelsea Therapeutics Announces Presentation of Northera(TM) (droxidopa) Study 306 Data at the American Academy of Neurology Annual Meeting
[at noodls] – CHARLOTTE, N.C., March 19, 2013 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Dr. Stuart Isaacson, Clinical Associate Professor, Department of Neurology, … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click here to view […]
Chelsea Therapeutics to Present at the 25th Annual ROTH Conference
[at noodls] – CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25TH Annual ROTH Conference at 3:30 PM PT on Tuesday, March 19, … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click here to […]
US close: Stocks slump on Fed minutes
moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click here to view […]
Chelsea Therapeutics Receives FDA Guidance for a Northera(TM) (Droxidopa) NDA Resubmission With Study 306B
[at noodls] – Company to Resubmit NDA in Late Second Quarter 2013 Short-term Clinical Benefit Adequate to Support Approval Company to Host Conference Call Today at 9:00 AM ET CHARLOTTE, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click […]
Chelsea Therapeutics Announces Northera(TM) (Droxidopa) Study 306B Meets Primary Endpoint
[at noodls] – Northeraâ„¢ Demonstrated Statistically Significant Improvement Over Placebo in Reduction of Dizziness/Lightheadedness at Week 1 (p=0.018), the Primary Endpoint, and Standing Blood Pressure at Week 1 (p=0.032), … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboardSee who Chelsea is hiring next, click here to view […]
Chelsea Therapeutics Reports Third Quarter 2012 Financial Results
[at noodls] – Increasing Guidance for Year End Cash on Hand to $27 Million CHARLOTTE, N.C., Nov. 7, 2012 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboard […]
Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd International Symposium on the Autonomic Nervous System
[at noodls] – CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from a study of Northeraâ„¢ (droxidopa) in hypotensive individuals with spinal … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: Upcoming Clinical Results for CHTP’s Northera Could Rejuvenate The Stock
[ACN Newswire] – By David MoskowitzAfter being decimated earlier this year on the FDA rejection of Northera, shares of Chelsea Therapeutics (NASDAQ:CHTP) could be rejuvenated as new Phase III results are expected to be … moreView todays social media effects on CHTPView the latest stocks trending across Twitter. Click to view dashboard […]
